Aquestive stockholders elect directors, approve equity plan, reject charter amendment at 2023 annual meeting

Aquestive Therapeutics, Inc.

Gregory B. Brown and John S. Cochran elected as Class II directors with over 24.7M and 24.9M votes for, respectively.
Amendment to 2018 Equity Incentive Plan approved: 18.97M for, 7.27M against, 0.34M abstain.
Amendment to Amended and Restated Certificate of Incorporation not approved: 22.31M for, 3.25M against, 1.02M abstain (failed to meet required threshold).
Ratification of KPMG LLP as independent auditor for FY2023 approved: 40.09M for, 0.44M against, 0.20M abstain.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Aquestive Therapeutics, Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-21 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-21

Exact text from the filing

The appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023 was ratified. Votes For Votes Against Votes Abstaining 40,091,281 438,344 203,299

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Aquestive Therapeutics, Inc. shareholders approved Approval of an amendment to the 2018 Equity Incentive Plan at the 2023-06-21 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-06-21

Exact text from the filing

The proposal to approve an amendment to the 2018 Equity Incentive Plan was approved. Votes For Votes Against Votes Abstaining 18,972,308 7,272,348 343,991

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Aquestive Therapeutics, Inc. shareholders rejected Approval of an amendment to the Amended and Restated Certificate of Incorporation at the 2023-06-21 meeting.

Proposal: charter amendment
Outcome: failed
Meeting: 2023-06-21

Exact text from the filing

The proposal to approve an amendment to the Amended and Restated Certificate of Incorporation was not approved. Votes For Votes Against Votes Abstaining 22,312,401 3,252,699 1,021,036

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Aquestive Therapeutics, Inc. shareholders approved Election of Class II Director at the 2023-06-21 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-21

Exact text from the filing

The following director nominee was elected to serve as Class II member of the Board of Directors, to serve for a three-year term until the Company’s 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Nominee Votes For Votes Against Votes Abstaining Broker Non-Votes Gregory B. Brown, M.D. 24,757,783 — 1,830,864 14,144,277 John S. Cochran 24,886,102 — 1,702,545 14,144,277

View on SEC.gov

Browse all shareholder votes →

Aquestive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-023215

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.